ABIONYX PHARMA SA (ABNX.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ABNX - FR0012616852 - Common Stock
4.08 EUR
+0.21 (+5.43%)
ABNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 86 industry peers in the Biotechnology industry. ABNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ABNX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- ABNX had negative earnings in the past year.
- In the past year ABNX has reported a negative cash flow from operations.
- ABNX had negative earnings in each of the past 5 years.
- ABNX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -35.18%, ABNX perfoms like the industry average, outperforming 45.35% of the companies in the same industry.
- With a Return On Equity value of -83.55%, ABNX perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.18% | ||
| ROE | -83.55% | ||
| ROIC | N/A |
ROA(3y)-27.55%
ROA(5y)-25.53%
ROE(3y)-53.79%
ROE(5y)-48.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ABNX has a Gross Margin of 17.78%. This is in the lower half of the industry: ABNX underperforms 60.47% of its industry peers.
- In the last couple of years the Gross Margin of ABNX has declined.
- ABNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.52%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ABNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ABNX has been increased compared to 1 year ago.
- The number of shares outstanding for ABNX has been increased compared to 5 years ago.
- Compared to 1 year ago, ABNX has an improved debt to assets ratio.
2.2 Solvency
- ABNX has an Altman-Z score of 9.92. This indicates that ABNX is financially healthy and has little risk of bankruptcy at the moment.
- ABNX has a Altman-Z score of 9.92. This is amongst the best in the industry. ABNX outperforms 87.21% of its industry peers.
- ABNX has a Debt/Equity ratio of 0.59. This is a neutral value indicating ABNX is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.59, ABNX is in line with its industry, outperforming 52.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.59 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.92 |
ROIC/WACCN/A
WACC8.1%
2.3 Liquidity
- A Current Ratio of 1.40 indicates that ABNX should not have too much problems paying its short term obligations.
- ABNX has a Current ratio of 1.40. This is in the lower half of the industry: ABNX underperforms 61.63% of its industry peers.
- ABNX has a Quick Ratio of 1.35. This is a normal value and indicates that ABNX is financially healthy and should not expect problems in meeting its short term obligations.
- ABNX has a Quick ratio of 1.35. This is comparable to the rest of the industry: ABNX outperforms 40.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
- The earnings per share for ABNX have decreased strongly by -28.06% in the last year.
- Looking at the last year, ABNX shows a very negative growth in Revenue. The Revenue has decreased by -10.91% in the last year.
- Measured over the past years, ABNX shows a very strong growth in Revenue. The Revenue has been growing by 88.92% on average per year.
EPS 1Y (TTM)-28.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.64%
Revenue 1Y (TTM)-10.91%
Revenue growth 3Y88.92%
Revenue growth 5YN/A
Sales Q2Q%-9.6%
3.2 Future
- Based on estimates for the next years, ABNX will show a very negative growth in Earnings Per Share. The EPS will decrease by -52.66% on average per year.
- Based on estimates for the next years, ABNX will show a very strong growth in Revenue. The Revenue will grow by 70.26% on average per year.
EPS Next Y-34.37%
EPS Next 2Y-68.63%
EPS Next 3Y-21.92%
EPS Next 5Y-52.66%
Revenue Next Year-1.09%
Revenue Next 2Y-0.54%
Revenue Next 3Y46.79%
Revenue Next 5Y70.26%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- ABNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABNX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as ABNX's earnings are expected to decrease with -21.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.63%
EPS Next 3Y-21.92%
5. Dividend
5.1 Amount
- No dividends for ABNX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ABIONYX PHARMA SA / ABNX.PA FAQ
What is the ChartMill fundamental rating of ABIONYX PHARMA SA (ABNX.PA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA.
What is the valuation status for ABNX stock?
ChartMill assigns a valuation rating of 0 / 10 to ABIONYX PHARMA SA (ABNX.PA). This can be considered as Overvalued.
What is the profitability of ABNX stock?
ABIONYX PHARMA SA (ABNX.PA) has a profitability rating of 1 / 10.